The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains α-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and α-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Compositions and methods for dietary enhancement of immune system function. The compositions may include zinc(+2) and a zinc ionophore. The compositions may include zinc(+2), a first zinc ionophore and a second zinc ionophore different from the first zinc ionophore. The zinc ionophore may include quercetin. The zinc ionophore may include a quinine compound. The compositions may include one or more of l-lysine, vitamin C, vitamin D, vitamin E, curcumin and epigallocatechin gallate. The compositions may be manufactured as dietary supplements. The methods may include dosing quantities of components of the compositions. The dosing quantities have been recommended by multi-month clinical experience during the COVID-19 pandemic.

Compositions and methods for dietary enhancement of immune system function. The compositions may include zinc(+2) and a zinc ionophore. The compositions may include zinc(+2), a first zinc ionophore and a second zinc ionophore different from the first zinc ionophore. The zinc ionophore may include quercetin. The zinc ionophore may include a quinine compound. The compositions may include one or more of l-lysine, vitamin C, vitamin D, vitamin E, curcumin and epigallocatechin gallate. The compositions may be manufactured as dietary supplements. The methods may include dosing quantities of components of the compositions. The dosing quantities have been recommended by multi-month clinical experience during the COVID-19 pandemic.

In some embodiments provided herein is a method of treating agitation associated with Alzheimer's disease in a subject, comprising administering to the subject therapeutically effective amounts of deuterated [d6]-dextromethorphan hydrobromide (d6-DM) and quinidine sulfate, wherein the subject is a patient that has been diagnosed as having Alzheimer's disease, wherein the method comprises determining the Cohen-Mansfield agitation inventory (CMAI) total score in the patient prior to said administration.

In some embodiments provided herein is a method of treating agitation associated with Alzheimer's disease in a subject, comprising administering to the subject therapeutically effective amounts of deuterated [d6]-dextromethorphan hydrobromide (d6-DM) and quinidine sulfate, wherein the subject is a patient that has been diagnosed as having Alzheimer's disease, wherein the method comprises determining the Cohen-Mansfield agitation inventory (CMAI) total score in the patient prior to said administration.

The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs to the polymer for treatment of specific diseases or conditions in a patient. The resulting conjugates display moderate stability or controlled drug release, and allows for delivery and release of drugs and other therapeutic moieties to tissues/cells that express scavenger receptor A1 in a controlled manner.

A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO) or absent DMSO.

A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO) or absent DMSO.

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.